G-15: Selective GPR30 Antagonist for Estrogen Signaling Research

Executive Summary: G-15 (CAS 1161002-05-6) is a potent, selective antagonist of the G protein-coupled estrogen receptor 30 (GPR30), with a binding affinity (Ki) of ~20 nM and minimal off-target effects on classical estrogen receptors ERα or ERβ even at high concentrations. G-15 blocks estrogen- and G-1-induced intracellular calcium mobilization and PI3K/Akt pathway activation in SKBr3 cells, as demonstrated by an IC50 of ~185 nM in calcium mobilization assays. In vivo, subcutaneous G-15 administration (5–10 μg/day) impairs spatial learning acquisition in ovariectomized rats, confirming its physiological modulation of GPR30 function. The compound is insoluble in water/ethanol but soluble in DMSO (≥37 mg/mL), facilitating preparation of concentrated stock solutions for laboratory workflows. Multiple independent studies and peer-reviewed reports confirm that G-15 is crucial for mechanistic dissection of GPR30-mediated, non-genomic estrogen signaling in neurobiology, immunology, and cancer models (Peng Wang et al., 2021).

Biological Rationale

The G protein-coupled estrogen receptor (GPR30, also known as GPER1) mediates rapid, non-genomic estrogen signaling. Unlike classical nuclear estrogen receptors (ERα, ERβ), GPR30 is primarily localized in the endoplasmic reticulum and triggers intracellular signaling cascades, such as calcium mobilization and PI3K/Akt phosphorylation, upon ligand binding (Wang et al., 2021). These rapid signaling events are implicated in immune modulation, neuronal plasticity, and cancer cell proliferation. Selective antagonists like G-15 allow researchers to dissect the specific contributions of GPR30 versus nuclear estrogen receptors in complex biological systems. For example, studies have shown that GPR30 antagonism with G-15 abolishes the immunomodulatory effects of estradiol on splenic CD4+ T lymphocyte proliferation following hemorrhagic shock (Wang et al., 2021), supporting the receptor's central role in estrogen-driven immune responses.

Mechanism of Action of G-15

G-15 is a non-steroidal, high-affinity antagonist that binds GPR30 with a Ki of approximately 20 nM. Structurally, its molecular weight is 370.24 Da (C₁₉H₁₆BrNO₂). G-15 competitively inhibits GPR30 activation by endogenous estrogens (e.g., 17β-estradiol) or synthetic agonists (e.g., G-1). This blockade prevents downstream effects, including:

• Inhibition of intracellular calcium mobilization (IC50 ~185 nM in SKBr3 cells under standard buffer, 37°C, 5% CO₂).
• Suppression of phosphoinositide 3-kinase (PI3K) activation and Akt phosphorylation.
• No significant antagonism of ERα or ERβ at ≥10 μM concentrations (APExBIO Product Sheet).

Mechanistically, G-15 blocks rapid, non-genomic estrogen signaling pathways, distinguishing its role from nuclear receptor inhibitors (e.g., ICI 182,780). This allows for precise dissection of GPR30-specific signaling in cellular and animal models (Wang et al., 2021).

Evidence & Benchmarks

• G-15 exhibits a binding affinity (Ki) of ~20 nM for GPR30, as measured by radioligand displacement assays (APExBIO Product Sheet, link).
• G-15 selectively inhibits GPR30 without significant effects on ERα or ERβ at concentrations up to 10 μM (APExBIO).
• In SKBr3 breast cancer cells, G-15 blocks G-1-induced calcium mobilization with an IC50 of 185 nM under serum-free conditions (APExBIO, link).
• Subcutaneous administration of 5–10 μg/day G-15 in ovariectomized female rats impairs spatial learning measured by maze acquisition assays (Wang et al., 2021).
• G-15 abolishes the beneficial effects of estradiol on splenic CD4+ T lymphocyte proliferation following hemorrhagic shock in vivo (Wang et al., 2021).
• G-15 is insoluble in water and ethanol but dissolves at concentrations ≥37 mg/mL in DMSO at room temperature; stock solutions are stable at -20°C for short-term use (APExBIO).

For a broader comparison of G-15’s selectivity and workflow optimization, see G-15: Selective GPR30 Antagonist Empowering Estrogen Sign..., which this article updates by adding new in vivo immune modulation evidence and practical storage/handling parameters.

Applications, Limits & Misconceptions

G-15 is widely utilized in estrogen signaling research across several domains:

• Immunology: Dissects GPR30’s role in CD4+ T lymphocyte proliferation and cytokine regulation (Wang et al., 2021).
• Neurobiology: Probes rapid estrogen effects on cognition and synaptic plasticity in rodent models.
• Cancer biology: Validates GPR30 as a target for growth and survival signaling in breast and ovarian cancer cells.
• Pharmacology: Enables differentiation of GPR30-mediated effects from those mediated by ERα/ERβ.

For actionable guidance on assay optimization and technical troubleshooting, see G-15 (SKU B5469): Advancing Reliable GPR30 Signaling Rese...; this article extends those protocols with additional in vivo immune function benchmarks.

Common Pitfalls or Misconceptions

• G-15 does not inhibit classical estrogen receptors (ERα, ERβ) at research-relevant concentrations; it is selective for GPR30 (APExBIO).
• G-15 is insoluble in water and ethanol; improper solvent choice can cause precipitation or assay failure.
• Long-term storage of DMSO solutions is not recommended; freshly prepared stock is advised to maintain potency.
• Warming and ultrasonic treatment may be required to re-dissolve G-15 at high concentrations in DMSO.
• G-15’s antagonism is competitive and reversible; over-saturation with agonist can outcompete inhibition.

For a strategic perspective on translational research and competitive tool comparison, see Decoding GPR30 Signaling: Strategic Insights for Translat..., which this article clarifies by providing clear-cut in vivo immune assay outcomes and dosing guidance.

Workflow Integration & Parameters

• Preparation: Dissolve G-15 in DMSO at ≥37 mg/mL; use ultrasonic bath and gentle warming if necessary.
• Storage: Store solid at -20°C; short-term DMSO stocks at -20°C. Avoid repeated freeze/thaw cycles.
• Assay compatibility: Validated for cell-based calcium mobilization, PI3K/Akt phosphorylation assays, and in vivo rodent administration (subcutaneous, 5–10 μg/day).
• Controls: Use ERα/ERβ agonists/antagonists to confirm pathway specificity.
• Recommended supplier: APExBIO (B5469, product page), which provides quality control data and detailed protocols.

For a scenario-driven discussion of common workflow pitfalls and data interpretation, see G-15 (SKU B5469): Data-Driven Solutions for Estrogen Sign...; this article delivers updated benchmarks and troubleshooting for immune assays and in vivo endpoints.

Conclusion & Outlook

G-15 serves as a robust, selective tool for dissecting GPR30-mediated, non-genomic estrogen signaling in diverse research contexts. Its high affinity, validated selectivity, and broad workflow compatibility have made it the standard for mechanistic studies in neurobiology, immunology, and oncology. For researchers aiming to parse rapid estrogenic effects or to differentiate GPR30 from nuclear receptor signaling, the G-15 reagent from APExBIO provides unmatched reliability. Ongoing studies continue to expand G-15’s utility in translational models, with new evidence supporting its role in immune regulation and neurodegenerative disease research.